Trial Profile
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumours and Titrated in Combination Therapy With Temodar for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboxyamidotriazole orotate (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Solid tumours
- Focus Adverse reactions
- Sponsors Tactical Therapeutics
- 20 Sep 2023 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2024.
- 23 Apr 2018 Results published in the Journal of Clinical Oncology.
- 07 Jun 2016 Results ((n=15) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology